

## Special Issue

# Cell-Free Nucleic Acids as Precision Biomarkers for Therapeutic Decision-Making Across Diseases

### Message from the Guest Editor

Cell-free nucleic acids (cfNAs), including circulating tumor DNA (ctDNA), cell-free DNA (cfDNA), and RNA species such as mRNA, microRNA, and long non-coding RNA, are emerging as powerful biomarkers for liquid biopsy. The most established clinical applications are in oncology, where the U.S. FDA has approved cfNA-based liquid biopsy assays to guide targeted therapies against EGFR, KRAS, PIK3CA, MET, ALK, and PARP. In prenatal and maternal–fetal medicine, fetal RHD genotyping from maternal plasma enables targeted prophylaxis in RhD-negative pregnancies. In transplantation, donor-derived cfDNA is increasingly used to monitor rejection and guide immunosuppressive therapy. Additionally, cfNAs are being studied for cardiovascular disease, to evaluate tissue injury, and in infectious diseases through pathogen cfDNA sequencing, which may inform antimicrobial strategies. We invite reviews, original research articles, and methodological studies on cfNA-based liquid biopsy, including biomarker discovery, analytical and computational methods, machine learning prediction, and translational applications across various diseases.

### Guest Editor

Dr. Manny D. Bacolod

Department of Microbiology and Immunology, Weill Cornell Medical College, New York, NY 10065, USA

### Deadline for manuscript submissions

31 August 2026



## Journal of Personalized Medicine

an Open Access Journal  
by MDPI

CiteScore 6.0  
Indexed in PubMed




[mdpi.com/si/255142](https://mdpi.com/si/255142)

*Journal of Personalized  
Medicine*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[jpm@mdpi.com](mailto:jpm@mdpi.com)

[mdpi.com/journal/](https://mdpi.com/journal/)

[jpm](https://jpm.mdpi.com)





# Journal of Personalized Medicine

---

an Open Access Journal  
by MDPI

---

CiteScore 6.0  
Indexed in PubMed



[mdpi.com/journal/  
jpm](https://mdpi.com/journal/jpm)



## About the Journal

### Message from the Editor-in-Chief

*Journal of Personalized Medicine (JPM)*, ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. *JPM* publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, 'omics association analysis). *JPM* is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

---

### Editor-in-Chief

Prof. Dr. Kenneth P.H. Pritzker

Department of Laboratory Medicine and Pathobiology, Department of Surgery, University of Toronto, 6 Queens Pk Crescent W.F, Toronto, ON M5S 3H2, Canada

---

### Author Benefits

#### High Visibility:

indexed within Scopus, PubMed, PMC, Embase, and other databases.

#### Journal Rank:

CiteScore - Q1 (Medicine (miscellaneous))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21.5 days after submission; acceptance to publication is undertaken in 3.5 days (median values for papers published in this journal in the first half of 2025).